ERBB2 and neoplasm: Besides, treatment of mice with trastuzumab and either an agent that blocks PD-1 or PD-L1, resulted in greater tumor regression compared with trastuzumab alone, suggesting an important role of checkpoint-inhibitors in HER2+ BC.